US price-fixing litigation targeting Teva has been selected as a priority for trial, making it a “bellwether” case, as part of the wider ongoing US investigation into generic price-fixing allegations.
Teva Chosen As 'Bellwether' In US Price-Fixing Litigation
Case Involving Israeli Generics Giant Selected As Priority For Trial
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
More from Legal & IP
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.